MBRX vs. IMMX, LPCN, KALA, SIOX, NOVN, CPIX, STSA, NLTX, CRBP, and LUMO
Should you be buying Moleculin Biotech stock or one of its competitors? The main competitors of Moleculin Biotech include Immix Biopharma (IMMX), Lipocine (LPCN), Kala Pharmaceuticals (KALA), Sio Gene Therapies (SIOX), Novan (NOVN), Cumberland Pharmaceuticals (CPIX), Satsuma Pharmaceuticals (STSA), Neoleukin Therapeutics (NLTX), Corbus Pharmaceuticals (CRBP), and Lumos Pharma (LUMO). These companies are all part of the "pharmaceutical preparations" industry.
Moleculin Biotech vs.
Moleculin Biotech (NASDAQ:MBRX) and Immix Biopharma (NASDAQ:IMMX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.
Moleculin Biotech has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500. Comparatively, Immix Biopharma has a beta of -0.06, suggesting that its stock price is 106% less volatile than the S&P 500.
Moleculin Biotech's return on equity of -39.62% beat Immix Biopharma's return on equity.
Moleculin Biotech presently has a consensus price target of $10.50, suggesting a potential upside of 1,013.35%. Immix Biopharma has a consensus price target of $14.00, suggesting a potential upside of 610.66%. Given Moleculin Biotech's higher probable upside, research analysts plainly believe Moleculin Biotech is more favorable than Immix Biopharma.
Moleculin Biotech received 219 more outperform votes than Immix Biopharma when rated by MarketBeat users. However, 100.00% of users gave Immix Biopharma an outperform vote while only 60.33% of users gave Moleculin Biotech an outperform vote.
In the previous week, Moleculin Biotech had 6 more articles in the media than Immix Biopharma. MarketBeat recorded 7 mentions for Moleculin Biotech and 1 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 1.90 beat Moleculin Biotech's score of -0.32 indicating that Immix Biopharma is being referred to more favorably in the news media.
10.4% of Moleculin Biotech shares are held by institutional investors. Comparatively, 2.2% of Immix Biopharma shares are held by institutional investors. 3.7% of Moleculin Biotech shares are held by insiders. Comparatively, 51.3% of Immix Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Moleculin Biotech beats Immix Biopharma on 8 of the 12 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Moleculin Biotech Competitors List
